Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice

Increased liver de novo lipogenesis (DNL) is a hallmark of nonalcoholic steatohepatitis (NASH). A key enzyme controlling DNL upregulated in NASH is ATP citrate lyase (ACLY). In mice, inhibition of ACLY reduces liver steatosis, ballooning, and fibrosis and inhibits activation of hepatic stellate cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Desjardins, Eric M., Wu, Jianhan, Lavoie, Declan C.T., Ahmadi, Elham, Townsend, Logan K., Morrow, Marisa R., Wang, Dongdong, Tsakiridis, Evangelia E., Batchuluun, Battsetseg, Fayyazi, Russta, Kwiecien, Jacek M., Tsakiridis, Theodoros, Lally, James S.V., Paré, Guillaume, Pinkosky, Stephen L., Steinberg, Gregory R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518624/
https://www.ncbi.nlm.nih.gov/pubmed/37729871
http://dx.doi.org/10.1016/j.xcrm.2023.101193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518624/
https://www.ncbi.nlm.nih.gov/pubmed/37729871
http://dx.doi.org/10.1016/j.xcrm.2023.101193

Ejemplares similares